Life Extension Skin Care Sale

Life Extension Magazine

LE Magazine October 2005
image

Why Our Arteries Become Clogged As We Age

By John Colman

Conclusion

Atherosclerosis remains the number-one cause of death and disability in the United States. The endothelial cells that line blood vessels are crucial to maintaining vascular integrity. Endothelial dysfunction is a critical factor in the initiation and progression of cardiovascular disease.

Two natural compounds—propionyl-l-carnitine (PLC) and PEAK ATP™—offer promise in restoring and maintaining healthy endothelial function while supporting cellular energy metabolism. PLC provides energy to the heart and vascular cells by promoting optimal energy metabolism in the mitochondria. PEAK ATP™ boosts energy levels and vascular health by restoring youthful levels of ATP in red blood cells, tissues, and organs.

Together, these two powerful compounds support optimal cellular energy and vascular health.

References

1. Selnes OA, Grega MA, Borowicz LM, Jr., et al. Self-reported memory symptoms with coronary artery disease: a prospective study of CABG patients and nonsurgical controls. Cogn Behav Neurol. 2004 Sep;17(3):148-56.

2. Toner I, Peden CJ, Hamid SK, et al. Magnetic resonance imaging and neuropsychological changes after coronary artery bypass graft surgery: preliminary findings. J Neurosurg Anesthesiol. 1994 Jul;6(3):163-9.

3. Rasouli ML, Nasir K, Blumenthal RS, et al. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis. 2005 Jul;181(1):159-65.

4. Xie LQ, Wang X. C-reactive protein and atherosclerosis. Sheng Li Ke Xue Jin Zhan. 2004 Apr;35(2):113-8.

5. Verma S. C-reactive protein incites atherosclerosis. Can J Cardiol. 2004 Aug;20 Suppl B29B-31B.

6. Stochmal E, Szurkowska M, Czarnecka D, et al. Association of coronary atherosclerosis with insulin resistance in patients with impaired glucose tolerance. Acta Cardiol. 2005 Jun;60(3):325-31.

7. Sharrett AR, Patsch W, Sorlie PD, et al. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb. 1994 Jul;14(7):1098-104.

8. Muis MJ, Bots ML, Bilo HJ, et al. High cumulative insulin exposure: a risk factor of atherosclerosis in type 1 diabetes? Atherosclerosis. 2005 Jul;181(1):185-92.

9. Malkin CJ, Pugh PJ, Jones RD, Jones TH, Channer KS. Testosterone as a protective factor against atherosclerosis—immunomodulation and influence upon plaque development and stability. J Endocrinol. 2003 Sep;178(3):373-80.

10. Howes PS, Zacharski LR, Sullivan J, Chow B. Role of stored iron in atherosclerosis. J Vasc Nurs. 2000 Dec;18(4):109-14.

11. Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs. 2005;5(3):141-54.

12. de Valk B, Marx JJ. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med. 1999 Jul 26;159(14):1542-8.

13. Drexel H, Amann FW, Beran J, et al. Plasma triglycerides and three lipoprotein cholesterol fractions are independent predictors of the extent of coronary atherosclerosis. Circulation. 1994 Nov;90(5):2230-5.

14. Chau LY. Iron and atherosclerosis. Proc Natl Sci Counc Repub China B. 2000 Oct;24(4):151-5.

15. Bolad I, Delafontaine P. Endothelial dysfunction: its role in hypertensive coronary disease. Curr Opin Cardiol. 2005 Jul;20(4):270-4.

16. Chakraphan D, Sridulyakul P, Thipakorn B, et al. Attenuation of endothelial dysfunction by exercise training in STZ-induced diabetic rats. Clin Hemorheol Microcirc. 2005;32(3):217-26.

17. Harvey PJ, Picton PE, Su WS, et al. Exercise as an alternative to oral estrogen for amelioration of endothelial dysfunction in postmenopausal women. Am Heart J. 2005 Feb;149(2):291-7.

18. Hink U, Tsilimingas N, Wendt M, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus: therapeutic implications. Treat Endocrinol. 2003;2(5):293-304.

19. Lteif AA, Han K, Mather KJ. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Circulation. 2005 Jul 5;112(1):32-8.

20. Newby DE, McLeod AL, Uren NG, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation. 2001 Apr 17;103(15):1936-41.

21. Panus C, Mota M, Vladu D, Vanghelie L, Raducanu CL. The endothelial dysfunction in diabetes mellitus. Rom J Intern Med. 2003;41(1):27-33.

22. Papamichael CM, Aznaouridis KA, Stamatelopoulos KS, et al. Endothelial dysfunction and type of cigarette smoked: the impact of ‘light’ versus regular cigarette smoking. Vasc Med. 2004 May;9(2):103-5.

23. Suvorava T, Lauer N, Kojda G. Physical inactivity causes endothelial dysfunction in healthy young mice. J Am Coll Cardiol. 2004 Sep 15;44(6):1320-7.

24. Toikka JO, Ahotupa M, Viikari JS, et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999 Nov 1;147(1):133-8.

25. Vakkilainen J, Makimattila S, Seppala-Lindroos A, et al. Endothelial dysfunction in men with small LDL particles. Circulation. 2000 Aug 15;102(7):716-21.

26. Apetrei E, Ciobanu-Jurcut R, Rugina M, Gavrila A, Uscatescu V. C-reactive protein, prothrombotic imbalance and endothelial dysfunction in acute coronary syndromes without ST elevation. Rom J Intern Med. 2004;42(1):95-102.

27. Kunes P. C-reactive protein in the pathogenesis of atherosclerosis: advantage and pitfalls of the “Mainz hypothesis.” Cas Lek Cesk. 2005;144(1):25-31.

28. Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med. 2005 Aug;22(8):999-1004.

29. Sainani GS, Sainani R. Homocysteine and its role in the pathogenesis of atherosclerotic vascular disease. J Assoc Physicians India. 2002 May;50 Suppl16-23.

30. Drouet L, Bal dit SC. Is fibrinogen a predictor or a marker of the risk of cardiovascular events? Therapie. 2005 Mar;60(2):125-36.

31. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999 Sep;48(9):1856-62.

32. Ceriello A. Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr Metab. 1999 Feb;12(1):42-6.

33. Cubeddu LX, Hoffmann IS. Insulin resistance and upper-normal glucose levels in hypertension: a review. J Hum Hypertens. 2002 Mar;16 Suppl 1S52-5.

34. Nowak A, Stankiewicz W, Szczesniak L, Korman E. Glucosamine in the blood serum of young people with diabetes mellitus type 1. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 1999;5(2):97-101.

35. Steinbaum SR. The metabolic syndrome: an emerging health epidemic in women. Prog Cardiovasc Dis. 2004 Jan;46(4):321-36.

36. Woodman RJ, Chew GT, Watts GF. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Drugs. 2005;65(1):31-74.

37. Brandes RP, Fleming I, Busse R. Endothelial aging. Cardiovasc Res. 2005 May 1;66(2):286-94.

38. Kravchenko J, Goldschmidt-Clermont PJ, Powell T, et al. Endothelial progenitor cell therapy for atherosclerosis: the philosopher’s stone for an aging population? Sci Aging Knowledge Environ. 2005 Jun 22;2005(25):e18.

39. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 1993;22 Suppl 4:S1-14.

40. Available at: http://www.medreviews.com/ pdfs/articles/RIU_5Suppl7_S21.pdf. Accessed April 20, 2005.

41. Available at: http://www.escardio.org/knowledge/cardiology_practice/ejournal_vol1/Vol1_no16.htm. Accessed April 20, 2005.

42. Cavallini G, Caracciolo S, Vitali G, Modenini F, Biagiotti G. Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology. 2004 Apr;63(4):641-6.

43. Vermeulen RC, Scholte HR. Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome. Psychosom Med. 2004 Mar;66(2):276-82.

44. Bertelli A, Conte A, Ronca G, Segnini D, Yu G. Protective effect of propionyl carnitine against peroxidative damage to arterial endothelium membranes. Int J Tissue React. 1991;13(1):41-3.

45. Amico-Roxas M, Caruso A, Cutuli VM, de Bernardis E, Leonardi G. Inhibitory effects of propionyl-L-carnitine on plasma extravasation induced by irritants in rodents. Drugs Exp Clin Res. 1993;19(5):213-7.

46. Bertelli A, Conte A, Palmieri L, et al. Effect of propionyl carnitine on energy charge and adenine nucleotide content of cardiac endothelial cells during hypoxia. Int J Tissue React. 1991;13(1):37-40.

47. Wiseman LR, Brogden RN. Propionyl-L-carnitine. Drugs Aging. 1998 Mar;12(3):243-8.

48. Ferrari R, Merli E, Cicchitelli G, et al. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann NY Acad Sci. 2004 Nov;1033:79-91.

49. Hiatt WR. Carnitine and peripheral arterial disease. Ann NY Acad Sci. 2004 Nov;1033:92-8.

50. Anand I, Chandrashekhan Y, De Giuli F, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther. 1998 Jul;12(3):291-9.

51. Sayed-Ahmed MM, Salman TM, Gaballah HE, et al. Propionyl-L-carnitine as protector against adriamycin-induced cardiomyopathy. Pharmacol Res. 2001 Jun;43(6):513-20.

52. Bartels GL, Remme WJ, Pillay M, Schonfeld DH, Kruijssen DA. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol. 1994 Jul 15;74(2):125-30.

53. Spagnoli LG, Orlandi A, Marino B, et al. Propionyl-L-carnitine prevents the progression of atherosclerotic lesions in aged hyperlipemic rabbits. Atherosclerosis. 1995 Apr 7;114(1):29-44.

54. Barker GA, Green S, Askew CD, Green AA, Walker PJ. Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease. Med Sci Sports Exerc. 2001 Sep;33(9):1415-22.

55. Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J. 1992 Feb;13(2):251-5.

56. Kaiser KP, Feinendegen LE. Planar scintigraphy versus PET in measuring fatty acid metabolism of the heart. Herz. 1987 Feb;12(1):41-50.

57. Torielli L, Conti F, Cinato E, et al. Alterations in energy metabolism of hypertrophied rat cardiomyocytes: influence of propionyl-L-carnitine. J Cardiovasc Pharmacol. 1995 Sep;26(3):372-80.

58. Bueno R, Alvarez de Sotomayor M, Perez-Guerrero C, et al. L-carnitine and propionyl-L-carnitine improve endothelial dysfunction in spontaneously hypertensive rats: Different participation of NO and COX-products. Life Sci. 2005 Jun 13.

59. Broderick TL, Haloftis G, Paulson DJ. L-propionylcarnitine enhancement of substrate oxidation and mitochondrial respiration in the diabetic rat heart. J Mol Cell Cardiol. 1996 Feb;28(2):331-40.

60. Brevetti G, Perna S, Sabba C, Martone VD, Condorelli M. Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol. 1995 Nov 15;26(6):1411-16.

61. Rabini RA, Petruzzi E, Staffolani R, et al. Diabetes mellitus and subjects’ ageing: a study on the ATP content and ATP-related enzyme activities in human erythrocytes. Eur J Clin Invest. 1997 Apr;27(4):327-32.

62. Kichenin K, Decollogne S, Angignard J, Seman M. Cardiovascular and pulmonary response to oral administration of ATP in rabbits. J Appl Physiol. 2000 Jun;88(6):1962-8.

63. Kichenin K, Seman M. Chronic oral administration of ATP modulates nucleoside transport and purine metabolism in rats. J Pharmacol Exp Ther. 2000 Jul;294(1):126-33.

64. US patent 5,049,372. US patent 5,227,371.

65. Van Aken H, Puchstein C, Fitch W, Graham DI. Haemodynamic and cerebral effects of ATP-induced hypotension. Br J Anaesth. 1984 Dec;56(12):1409-16.

66. Rosenmeier JB, Hansen J, Gonzalez-Alonso J. Circulating ATP-induced vasodilatation overrides sympathetic vasoconstrictor activity in human skeletal muscle. J Physiol. 2004 Jul 1;558(Pt 1):351-65.

67. Gonzalez-Alonso J, Olsen DB, Saltin B. Erythrocyte and the regulation of human skeletal muscle blood flow and oxygen delivery: role of circulating ATP. Circ Res. 2002 Nov 29;91(11):1046-55.

68. Ellsworth ML, Forrester T, Ellis CG, Dietrich HH. The erythrocyte as a regulator of vascular tone. Am J Physiol. 1995 Dec;269(6 Pt 2):H2155-161.

69. Sprague RS, Stephenson AH, Ellsworth ML, Keller C, Lonigro AJ. Impaired release of ATP from red blood cells of humans with primary pulmonary hypertension. Exp Biol Med (Maywood.). 2001 May;226(5):434-9.

70. Sprague RS, Ellsworth ML, Stephenson AH, Kleinhenz ME, Lonigro AJ. Deformation-induced ATP release from red blood cells requires CFTR activity. Am J Physiol. 1998 Nov;275(5 Pt 2):H1726-32.

71. Kitakaze M, Minamino T, Node K, et al. Adenosine and cardioprotection in the diseased heart. Jpn Circ J. 1999 Apr;63(4):231-43.